{
    "info": {
        "nct_id": "NCT06330805",
        "official_title": "A Comparison of Orgovyx (Relugolix) vs Eligard (Leuprolide) on Cardiovascular Function and Biomarkers During Standard of Care Combined ADT (Androgen Deprivation Therapy)-Radiation for Prostate Cancer",
        "inclusion_criteria": "* Pathologically proven diagnosis of adenocarcinoma of the prostate within 270 days prior to registration.\n* Unfavorable intermediate risk prostate cancer, defined as having ALL the following bulleted criteria:\n\n  * Has at least one intermediate risk factor (IRF):\n\n    * Prostate-specific antigen (PSA) 10-20 ng/mL\n    * Clinical stage tumor (T)2b-c (digital rectal exam [DRE] and/or imaging) by American Joint Committee on Cancer (AJCC) 8th edition\n    * Gleason Score 7 (Gleason 3+4 or 4+3 [International Society of Urological Pathology [ISUP] grade group 2-3])\n  * Has one or more of the following \"unfavorable\" intermediate-risk designators:\n\n    * > 1 IRF\n    * Gleason 4+3=7 (ISUP grade group 3)\n    * ≥ 50% of biopsy cores positive\n\n      * Biopsies may include \"sextant\" sampling of right/left regions of the prostate, often labeled base, mid-gland and apex. All such \"sextant\" biopsy cores should be counted. Men may also undergo \"targeted\" sampling of prostate lesions (guided by MRI, ultrasound or other approaches). A targeted lesion that is biopsied more than once and demonstrates cancer (regardless of number of targeted cores involved) should count as a single additional positive core sampled and positive. In cases of uncertainty, count the biopsy sampling as sextant core(s).\n    * Absence of high-risk features\n* Appropriate stage based on the following diagnostic workup:\n\n  * History/physical examination within 120 days prior to registration\n  * Negative bone imaging (M0) with Tc-99m bone scan or fluciclovine (18F) sodium fluoride (NaF) positron emission tomography (PET) within 120 days prior to registration\n  * Clinically negative lymph nodes (N0) as established by conventional imaging (pelvic +/- abdominal CT or MRI), within 120 days prior to registration (lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.0 cm in short axis and/or if biopsy is negative)\n  * Prostate specific membrane antigen (PSMA) or fluciclovine PET negative for nodal or distant metastatic disease is an acceptable substitute for the above bone and pelvic imaging\n* Age ≥ 18\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 120 days prior to registration.\n* Non-castrate testosterone level (> 50 ng/dL) within 120 days prior to registration.\n* Absolute neutrophil ≥ 1,000 cells/mm^3 (within 120 days prior to registration)\n* Hemoglobin ≥ 10 g/dL (within 120 days prior to registration)\n* Platelet count ≥ 100,000 cells/mm^3 (within 120 days prior to registration)\n* Creatinine clearance (CrCl) ≥ 30 mL/min estimated by Cockcroft-Gault Equation (within 120 days prior to registration)\n\n  * For African American patients, CrCl ≥ 30 mL/min is estimated by the alternative formula that takes race into account\n* Total bilirubin: 1.5 ≤ institutional upper limit of normal (ULN) (within 120 days prior to registration)\n* Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic-pyruvic transaminase [SGPT]) ≤ 2.5 × institutional ULN (within 120 days prior to registration)\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Note: HIV testing is not required for eligibility for this protocol.\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n\nNote: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B).\n\n* For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n\n  * Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy.\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Previous radical surgery (prostatectomy) or any form of curative-intent ablation whether focal or whole-gland (e.g., cryosurgery, High-intensity focused ultrasound (HIFU), laser thermal ablation, etc.) for prostate cancer.\n* Definitive clinical or radiologic evidence of metastatic disease (M1).\n* Prior invasive malignancy (except non-melanomatous skin cancer) or hematologic malignancy unless disease free for a minimum of 3 years.\n* Prior radiotherapy to the prostate/pelvis region that would result in overlap of radiation therapy fields.\n* Previous bilateral orchiectomy.\n* Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate). ADT started prior to study registration is not allowed.\n* Prior use of 5-alpha-reductase inhibitors is allowed; however, it must be stopped ≥ 30 days prior to the pre-registration PSA measure for determining enrollment eligibility.\n* Prior testosterone replacement therapy is allowed; however, any replacement therapy must be stopped for at least 1 year prior to registration.\n* Severe, active co-morbidity defined as follows:\n\n  * Current/uncontrolled angina or arrhythmias\n  * New York Heart Association Functional Classification II-IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.)\n  * History of any condition that in the opinion of the investigator, would preclude participation in this study\n* Patients with significant obstructive urinary symptoms that are suspected to be secondary to prostate cancer and/or benign prostatic hypertrophy.\n* Disabilities that prevent performing moderate intensity exercise test with exercise (treadmill) stress test and muscle function tests (walking/gait assessments and grip strength).\n* Patients unable to tolerate MRI (e.g. claustrophobia), has contraindications to MRI (e.g. metals and implants incompatible with MRI), body habitus preventing MRI scanning, or allergy to gadolinium-based contrast.\n* Significant uncontrolled gastrointestinal (e.g. Crohn's disease, ulcerative colitis) or metabolic disease (e.g. diabetes, hyperlipidemia).\n* Active inflammatory or immune-related disease treated with steroids or immunosuppressive agents.\n* Inability to swallow oral pills.\n* High risk features, which includes any of the following:\n\n  * Gleason 8-10 [ISUP grade group 4-5]\n  * PSA>20\n  * cT3-4 by digital exam OR gross extra-prostatic extension on imaging [indeterminate MRI evidence will not count and the patient will be eligible]",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil ≥ 1,000 cells/mm^3 (within 120 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil ≥ 1,000 cells/mm^3 (within 120 days prior to registration)",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "cells/mm^3"
                            }
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 120 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate specific membrane antigen (PSMA) or fluciclovine PET negative for nodal or distant metastatic disease is an acceptable substitute for the above bone and pelvic imaging",
            "criterions": [
                {
                    "exact_snippets": "Prostate specific membrane antigen (PSMA) or fluciclovine PET negative for nodal or distant metastatic disease",
                    "criterion": "PSMA or fluciclovine PET scan",
                    "requirements": [
                        {
                            "requirement_type": "result for nodal metastatic disease",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "result for distant metastatic disease",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 within 120 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 120 days prior to registration",
                    "criterion": "ECOG Performance Status assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "time since assessment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Note: HIV testing is not required for eligibility for this protocol.",
            "criterions": [
                {
                    "exact_snippets": "HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on effective anti-retroviral therapy",
                    "criterion": "anti-retroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undetectable viral load within 6 months",
                    "criterion": "HIV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age ≥ 18",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin: 1.5 ≤ institutional upper limit of normal (ULN) (within 120 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin: 1.5 ≤ institutional upper limit of normal (ULN) (within 120 days prior to registration)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 120 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance (CrCl) ≥ 30 mL/min estimated by Cockcroft-Gault Equation (within 120 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance (CrCl) ≥ 30 mL/min estimated by Cockcroft-Gault Equation (within 120 days prior to registration)",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "estimation method",
                            "expected_value": "Cockcroft-Gault Equation"
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "within 120 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Appropriate stage based on the following diagnostic workup:",
            "criterions": [
                {
                    "exact_snippets": "Appropriate stage based on the following diagnostic workup",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "appropriateness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy.",
            "criterions": [
                {
                    "exact_snippets": "Known positive test for hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection",
                    "criterion": "hepatitis C virus ribonucleic acid (HCV RNA)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": [
                                "acute",
                                "chronic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the viral load becomes undetectable on suppressive therapy",
                    "criterion": "HCV RNA viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "on suppressive therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 10 g/dL (within 120 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 10 g/dL (within 120 days prior to registration)",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "within 120 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has one or more of the following \"unfavorable\" intermediate-risk designators:",
            "criterions": [
                {
                    "exact_snippets": "one or more of the following \"unfavorable\" intermediate-risk designators",
                    "criterion": "unfavorable intermediate-risk designators",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "designators"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History/physical examination within 120 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "History/physical examination within 120 days prior to registration",
                    "criterion": "history/physical examination",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gleason 4+3=7 (ISUP grade group 3)",
            "criterions": [
                {
                    "exact_snippets": "Gleason 4+3=7 (ISUP grade group 3)",
                    "criterion": "Gleason score",
                    "requirements": [
                        {
                            "requirement_type": "score pattern",
                            "expected_value": "4+3=7"
                        }
                    ]
                },
                {
                    "exact_snippets": "Gleason 4+3=7 (ISUP grade group 3)",
                    "criterion": "ISUP grade group",
                    "requirements": [
                        {
                            "requirement_type": "grade group",
                            "expected_value": "3"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.",
            "criterions": [
                {
                    "exact_snippets": "patients with a history of hepatitis C virus (HCV) infection must have been treated and cured",
                    "criterion": "history of hepatitis C virus (HCV) infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "treated and cured"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with HCV infection who are currently on treatment ... eligible if they have an undetectable HCV viral load",
                    "criterion": "current HCV infection on treatment",
                    "requirements": [
                        {
                            "requirement_type": "HCV viral load",
                            "expected_value": "undetectable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information.",
            "criterions": [
                {
                    "exact_snippets": "The patient or a legally authorized representative must provide study-specific informed consent prior to study entry",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for patients treated in the United States (U.S.), authorization permitting release of personal health information",
                    "criterion": "authorization for release of personal health information",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "United States"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has at least one intermediate risk factor (IRF):",
            "criterions": [
                {
                    "exact_snippets": "Has at least one intermediate risk factor (IRF)",
                    "criterion": "intermediate risk factor (IRF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "risk factor"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.",
            "criterions": [
                {
                    "exact_snippets": "evidence of chronic hepatitis B virus (HBV) infection",
                    "criterion": "chronic hepatitis B virus (HBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the HBV viral load must be undetectable on suppressive therapy, if indicated",
                    "criterion": "HBV viral load",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        },
                        {
                            "requirement_type": "therapy",
                            "expected_value": "on suppressive therapy, if indicated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinical stage tumor (T)2b-c (digital rectal exam [DRE] and/or imaging) by American Joint Committee on Cancer (AJCC) 8th edition",
            "criterions": [
                {
                    "exact_snippets": "Clinical stage tumor (T)2b-c (digital rectal exam [DRE] and/or imaging) by American Joint Committee on Cancer (AJCC) 8th edition",
                    "criterion": "tumor clinical stage (T)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "b"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "c"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "digital rectal exam [DRE] and/or imaging",
                    "criterion": "tumor staging method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "digital rectal exam (DRE)",
                                "imaging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "by American Joint Committee on Cancer (AJCC) 8th edition",
                    "criterion": "staging system version",
                    "requirements": [
                        {
                            "requirement_type": "staging system",
                            "expected_value": "AJCC 8th edition"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B).",
            "criterions": [
                {
                    "exact_snippets": "Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy.",
                    "criterion": "hepatitis B virus surface antigen (HBV sAg)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "infection status",
                            "expected_value": "no acute or chronic infection"
                        },
                        {
                            "requirement_type": "viral load",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "detectable"
                            }
                        },
                        {
                            "requirement_type": "suppressive therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B).",
                    "criterion": "hepatitis B immunity (anti-Hepatitis B surface antibody)",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically negative lymph nodes (N0) as established by conventional imaging (pelvic +/- abdominal CT or MRI), within 120 days prior to registration (lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.0 cm in short axis and/or if biopsy is negative)",
            "criterions": [
                {
                    "exact_snippets": "Clinically negative lymph nodes (N0) as established by conventional imaging (pelvic +/- abdominal CT or MRI), within 120 days prior to registration",
                    "criterion": "lymph node status",
                    "requirements": [
                        {
                            "requirement_type": "clinical status",
                            "expected_value": "N0 (clinically negative)"
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "conventional imaging",
                                "pelvic CT",
                                "abdominal CT",
                                "MRI"
                            ]
                        },
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.0 cm in short axis",
                    "criterion": "lymph node size (equivocal/questionable nodes)",
                    "requirements": [
                        {
                            "requirement_type": "size (short axis)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lymph nodes equivocal or questionable by imaging are eligible ... if biopsy is negative",
                    "criterion": "lymph node biopsy result (equivocal/questionable nodes)",
                    "requirements": [
                        {
                            "requirement_type": "biopsy result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Biopsies may include \"sextant\" sampling of right/left regions of the prostate, often labeled base, mid-gland and apex. All such \"sextant\" biopsy cores should be counted. Men may also undergo \"targeted\" sampling of prostate lesions (guided by MRI, ultrasound or other approaches). A targeted lesion that is biopsied more than once and demonstrates cancer (regardless of number of targeted cores involved) should count as a single additional positive core sampled and positive. In cases of uncertainty, count the biopsy sampling as sextant core(s).",
            "criterions": [
                {
                    "exact_snippets": "All such \"sextant\" biopsy cores should be counted.",
                    "criterion": "sextant biopsy cores",
                    "requirements": [
                        {
                            "requirement_type": "counting",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "A targeted lesion that is biopsied more than once and demonstrates cancer (regardless of number of targeted cores involved) should count as a single additional positive core sampled and positive.",
                    "criterion": "targeted lesion biopsy with cancer",
                    "requirements": [
                        {
                            "requirement_type": "counting as single positive core",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "In cases of uncertainty, count the biopsy sampling as sextant core(s).",
                    "criterion": "uncertain biopsy sampling",
                    "requirements": [
                        {
                            "requirement_type": "counting as sextant core(s)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate-specific antigen (PSA) 10-20 ng/mL",
            "criterions": [
                {
                    "exact_snippets": "Prostate-specific antigen (PSA) 10-20 ng/mL",
                    "criterion": "prostate-specific antigen (PSA) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "ng/mL"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 20,
                                        "unit": "ng/mL"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absence of high-risk features",
            "criterions": [
                {
                    "exact_snippets": "Absence of high-risk features",
                    "criterion": "high-risk features",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative bone imaging (M0) with Tc-99m bone scan or fluciclovine (18F) sodium fluoride (NaF) positron emission tomography (PET) within 120 days prior to registration",
            "criterions": [
                {
                    "exact_snippets": "Negative bone imaging (M0) with Tc-99m bone scan or fluciclovine (18F) sodium fluoride (NaF) positron emission tomography (PET) within 120 days prior to registration",
                    "criterion": "bone imaging",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "imaging_modality",
                            "expected_value": [
                                "Tc-99m bone scan",
                                "fluciclovine (18F) sodium fluoride (NaF) PET"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-castrate testosterone level (> 50 ng/dL) within 120 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Non-castrate testosterone level (> 50 ng/dL) within 120 days prior to registration.",
                    "criterion": "testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 120 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* > 1 IRF",
            "criterions": [
                {
                    "exact_snippets": "> 1 IRF",
                    "criterion": "IRF",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unfavorable intermediate risk prostate cancer, defined as having ALL the following bulleted criteria:",
            "criterions": [
                {
                    "exact_snippets": "Unfavorable intermediate risk prostate cancer",
                    "criterion": "prostate cancer risk group",
                    "requirements": [
                        {
                            "requirement_type": "risk group",
                            "expected_value": "unfavorable intermediate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically proven diagnosis of adenocarcinoma of the prostate within 270 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically proven diagnosis of adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "pathologically proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 270 days prior to registration",
                    "criterion": "diagnosis date",
                    "requirements": [
                        {
                            "requirement_type": "time_since_diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 270,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 100,000 cells/mm^3 (within 120 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100,000 cells/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "cells/mm^3"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within 120 days prior to registration",
                    "criterion": "platelet count measurement timing",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥ 50% of biopsy cores positive",
            "criterions": [
                {
                    "exact_snippets": "≥ 50% of biopsy cores positive",
                    "criterion": "biopsy cores positive",
                    "requirements": [
                        {
                            "requirement_type": "proportion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For African American patients, CrCl ≥ 30 mL/min is estimated by the alternative formula that takes race into account",
            "criterions": [
                {
                    "exact_snippets": "For African American patients",
                    "criterion": "race",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "African American"
                        }
                    ]
                },
                {
                    "exact_snippets": "CrCl ≥ 30 mL/min",
                    "criterion": "creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "estimated by the alternative formula that takes race into account",
                    "criterion": "creatinine clearance (CrCl) estimation method",
                    "requirements": [
                        {
                            "requirement_type": "estimation method",
                            "expected_value": "alternative formula that takes race into account"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate). ADT started prior to study registration is not allowed.",
            "criterions": [
                {
                    "exact_snippets": "Previous hormonal therapy, such as luteinizing hormone-releasing hormone (LHRH) agonists (e.g., leuprolide, goserelin, buserelin, triptorelin) or LHRH antagonist (e.g. degarelix), anti-androgens (e.g., flutamide, bicalutamide, cyproterone acetate).",
                    "criterion": "previous hormonal therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "ADT started prior to study registration is not allowed.",
                    "criterion": "androgen deprivation therapy (ADT) initiation",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "must not be started prior to study registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant uncontrolled gastrointestinal (e.g. Crohn's disease, ulcerative colitis) or metabolic disease (e.g. diabetes, hyperlipidemia).",
            "criterions": [
                {
                    "exact_snippets": "Significant uncontrolled gastrointestinal (e.g. Crohn's disease, ulcerative colitis)",
                    "criterion": "gastrointestinal disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Significant uncontrolled ... metabolic disease (e.g. diabetes, hyperlipidemia)",
                    "criterion": "metabolic disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High risk features, which includes any of the following:",
            "criterions": [
                {
                    "exact_snippets": "High risk features",
                    "criterion": "high risk features",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous radical surgery (prostatectomy) or any form of curative-intent ablation whether focal or whole-gland (e.g., cryosurgery, High-intensity focused ultrasound (HIFU), laser thermal ablation, etc.) for prostate cancer.",
            "criterions": [
                {
                    "exact_snippets": "Previous radical surgery (prostatectomy)",
                    "criterion": "radical prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any form of curative-intent ablation whether focal or whole-gland (e.g., cryosurgery, High-intensity focused ultrasound (HIFU), laser thermal ablation, etc.) for prostate cancer",
                    "criterion": "curative-intent ablation for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with significant obstructive urinary symptoms that are suspected to be secondary to prostate cancer and/or benign prostatic hypertrophy.",
            "criterions": [
                {
                    "exact_snippets": "significant obstructive urinary symptoms",
                    "criterion": "obstructive urinary symptoms",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suspected to be secondary to prostate cancer and/or benign prostatic hypertrophy",
                    "criterion": "cause of obstructive urinary symptoms",
                    "requirements": [
                        {
                            "requirement_type": "suspected_cause",
                            "expected_value": [
                                "prostate cancer",
                                "benign prostatic hypertrophy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior testosterone replacement therapy is allowed; however, any replacement therapy must be stopped for at least 1 year prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Prior testosterone replacement therapy is allowed",
                    "criterion": "testosterone replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any replacement therapy must be stopped for at least 1 year prior to registration",
                    "criterion": "testosterone replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "cessation duration before registration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior radiotherapy to the prostate/pelvis region that would result in overlap of radiation therapy fields.",
            "criterions": [
                {
                    "exact_snippets": "Prior radiotherapy to the prostate/pelvis region",
                    "criterion": "prior radiotherapy to the prostate/pelvis region",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "would result in overlap of radiation therapy fields",
                    "criterion": "overlap of radiation therapy fields",
                    "requirements": [
                        {
                            "requirement_type": "potential for overlap",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients unable to tolerate MRI (e.g. claustrophobia), has contraindications to MRI (e.g. metals and implants incompatible with MRI), body habitus preventing MRI scanning, or allergy to gadolinium-based contrast.",
            "criterions": [
                {
                    "exact_snippets": "Patients unable to tolerate MRI (e.g. claustrophobia)",
                    "criterion": "MRI tolerance",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "contraindications to MRI (e.g. metals and implants incompatible with MRI)",
                    "criterion": "MRI contraindications",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "body habitus preventing MRI scanning",
                    "criterion": "body habitus",
                    "requirements": [
                        {
                            "requirement_type": "suitability for MRI scanning",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergy to gadolinium-based contrast",
                    "criterion": "allergy to gadolinium-based contrast",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe, active co-morbidity defined as follows:",
            "criterions": [
                {
                    "exact_snippets": "Severe, active co-morbidity",
                    "criterion": "co-morbidity",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Disabilities that prevent performing moderate intensity exercise test with exercise (treadmill) stress test and muscle function tests (walking/gait assessments and grip strength).",
            "criterions": [
                {
                    "exact_snippets": "Disabilities that prevent performing moderate intensity exercise test with exercise (treadmill) stress test",
                    "criterion": "disabilities preventing moderate intensity treadmill exercise stress test",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Disabilities that prevent performing ... muscle function tests (walking/gait assessments and grip strength)",
                    "criterion": "disabilities preventing muscle function tests (walking/gait assessments and grip strength)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA>20",
            "criterions": [
                {
                    "exact_snippets": "PSA>20",
                    "criterion": "PSA",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior invasive malignancy (except non-melanomatous skin cancer) or hematologic malignancy unless disease free for a minimum of 3 years.",
            "criterions": [
                {
                    "exact_snippets": "Prior invasive malignancy (except non-melanomatous skin cancer) ... unless disease free for a minimum of 3 years.",
                    "criterion": "prior invasive malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "non-melanomatous skin cancer"
                        },
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hematologic malignancy unless disease free for a minimum of 3 years.",
                    "criterion": "hematologic malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "disease free duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior use of 5-alpha-reductase inhibitors is allowed; however, it must be stopped ≥ 30 days prior to the pre-registration PSA measure for determining enrollment eligibility.",
            "criterions": [
                {
                    "exact_snippets": "Prior use of 5-alpha-reductase inhibitors is allowed",
                    "criterion": "5-alpha-reductase inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "prior use allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "it must be stopped ≥ 30 days prior to the pre-registration PSA measure for determining enrollment eligibility",
                    "criterion": "5-alpha-reductase inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing relative to pre-registration PSA measure",
                            "expected_value": "prior to"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of any condition that in the opinion of the investigator, would preclude participation in this study",
            "criterions": [
                {
                    "exact_snippets": "History of any condition that in the opinion of the investigator, would preclude participation in this study",
                    "criterion": "any condition precluding participation (per investigator judgment)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "would preclude participation in this study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active inflammatory or immune-related disease treated with steroids or immunosuppressive agents.",
            "criterions": [
                {
                    "exact_snippets": "Active inflammatory or immune-related disease",
                    "criterion": "inflammatory or immune-related disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "treated with steroids or immunosuppressive agents",
                    "criterion": "treatment with steroids or immunosuppressive agents",
                    "requirements": [
                        {
                            "requirement_type": "treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Definitive clinical or radiologic evidence of metastatic disease (M1).",
            "criterions": [
                {
                    "exact_snippets": "Definitive clinical or radiologic evidence of metastatic disease (M1)",
                    "criterion": "metastatic disease (M1)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evidence type",
                            "expected_value": [
                                "clinical",
                                "radiologic"
                            ]
                        },
                        {
                            "requirement_type": "certainty",
                            "expected_value": "definitive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* cT3-4 by digital exam OR gross extra-prostatic extension on imaging [indeterminate MRI evidence will not count and the patient will be eligible]",
            "criterions": [
                {
                    "exact_snippets": "cT3-4 by digital exam",
                    "criterion": "clinical T stage (cT) by digital exam",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "gross extra-prostatic extension on imaging",
                    "criterion": "gross extra-prostatic extension on imaging",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "indeterminate MRI evidence will not count and the patient will be eligible",
                    "criterion": "indeterminate MRI evidence",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gleason 8-10 [ISUP grade group 4-5]",
            "criterions": [
                {
                    "exact_snippets": "Gleason 8-10",
                    "criterion": "Gleason score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 8,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ISUP grade group 4-5",
                    "criterion": "ISUP grade group",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to swallow oral pills.",
            "criterions": [
                {
                    "exact_snippets": "Inability to swallow oral pills",
                    "criterion": "ability to swallow oral pills",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current/uncontrolled angina or arrhythmias",
            "criterions": [
                {
                    "exact_snippets": "Current ... angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "Current ... arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled ... arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous bilateral orchiectomy.",
            "criterions": [
                {
                    "exact_snippets": "Previous bilateral orchiectomy",
                    "criterion": "bilateral orchiectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* New York Heart Association Functional Classification II-IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.)",
            "criterions": [
                {
                    "exact_snippets": "New York Heart Association Functional Classification II-IV",
                    "criterion": "New York Heart Association Functional Classification",
                    "requirements": [
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "II",
                                "III",
                                "IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "known history or current symptoms of cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current symptoms",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of treatment with cardiotoxic agents",
                    "criterion": "treatment with cardiotoxic agents",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamic-pyruvic transaminase [SGPT]) ≤ 2.5 × institutional ULN (within 120 days prior to registration)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT]) ≤ 2.5 × institutional ULN (within 120 days prior to registration)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "institutional ULN"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 120 days prior to registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT)(serum glutamic-pyruvic transaminase [SGPT]) ≤ 2.5 × institutional ULN (within 120 days prior to registration)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "institutional ULN"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 120 days prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gleason Score 7 (Gleason 3+4 or 4+3 [International Society of Urological Pathology [ISUP] grade group 2-3])",
            "criterions": [
                {
                    "exact_snippets": "Gleason Score 7 (Gleason 3+4 or 4+3 [International Society of Urological Pathology [ISUP] grade group 2-3])",
                    "criterion": "Gleason score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "=",
                                "value": 7,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Gleason 3+4 or 4+3",
                    "criterion": "Gleason pattern",
                    "requirements": [
                        {
                            "requirement_type": "pattern",
                            "expected_value": [
                                "3+4",
                                "4+3"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "ISUP grade group 2-3",
                    "criterion": "ISUP grade group",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}